Curated News
By: NewsRamp Editorial Staff
May 07, 2026

NanoViricides to Present at D. Boral Capital Global Conference 2026

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • NanoViricides presents at D. Boral Capital conference, offering investors direct access to its leadership and antiviral pipeline.
  • NV-387 completed Phase I with no adverse events; NanoViricides now prepares for Phase II trials targeting multiple respiratory viruses.
  • NanoViricides' broad-spectrum antiviral NV-387 aims to treat RSV, COVID, and flu, potentially improving global health outcomes.
  • NanoViricides' drug candidate NV-387 shows efficacy against Monkeypox and Measles in animal models, expanding its antiviral reach.

Impact - Why it Matters

This news matters because NanoViricides is developing broad-spectrum antiviral drugs that could address major public health threats like COVID-19, RSV, influenza, and even Monkeypox. The company's participation in the D. Boral Capital Global Conference signals its readiness to advance NV-387 into Phase II trials, potentially bringing a new treatment option for viral infections that currently lack effective therapies. For investors, this conference provides a key opportunity to assess the company's progress and future prospects in the antiviral space.

Summary

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company specializing in nanomaterials for antiviral therapy, has announced its participation in the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City. During the event, Anil R. Diwan, Ph.D., the company’s president and executive chairman, will conduct one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET. This conference provides a platform for NanoViricides to showcase its innovative antiviral pipeline and engage with potential partners and shareholders. The full press release detailing the event is available at https://ibn.fm/YxQyd.

NanoViricides is advancing a portfolio of novel antiviral drugs, with its lead candidate NV-387 positioned as a broad-spectrum treatment for respiratory viral infections, including RSV, COVID-19, Long COVID, and Influenza. Notably, NV-387 has also demonstrated effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles. The company recently completed a Phase I human clinical trial for NV-387 in healthy volunteers, reporting no adverse events, and is now focused on advancing the drug into Phase II trials. Another key candidate is NV-HHV-1, designed to address all Herpesvirus infections, including HSV-1 (cold sores), HSV-2 (genital ulcers), VZV Shingles, and Chickenpox. However, the company notes that it cannot project an exact date for filing an Investigational New Drug (IND) application due to reliance on external collaborators and consultants. For the latest updates on NanoViricides, investors can visit the company’s newsroom at https://ibn.fm/NNVC.

The announcement was disseminated by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. InvestorWire offers a suite of services including press release syndication, editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and corporate communications solutions. By leveraging these resources, NanoViricides can effectively reach a wide audience of investors, influencers, and the general public. The conference participation underscores the company’s commitment to advancing its antiviral therapies and engaging with the investment community as it prepares for the next phase of clinical development.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides to Present at D. Boral Capital Global Conference 2026

blockchain registration record for this content.